We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 3.57% | 14.50 | 14.00 | 15.00 | 15.00 | 14.00 | 14.00 | 1,310,616 | 10:04:36 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 1.04M | -21.69M | -0.0832 | -1.74 | 37.78M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/3/2024 08:12 | As predicted the Gap is now filled Time to start buying. IMO, DYOR, NAI, GLA, & ATJ | cocorico2009 | |
18/3/2024 21:22 | Do you not know the reason why they do that?The reason they leave it so long is that the institutions involved in the placing have enough time to sell as many shares as possible before they announce the placing. The placing will be at a massive discount, but the institutions will have forward sold all the stock.I'm expecting an next news to be a placing at about 8 to 10 P. | kirk 6 | |
18/3/2024 16:13 | 11 months ago tomorrow Angle & Bioview signed a development agreement for a liquid biopsy circulating tumor cell (CTC) HER2 assay for breast cancer. "The development phase is estimated to take around a year to complete". In just under that year an abstract will be presented at the prestigious AACR towards the beginning of next month : "Results. Following IF, HER2 protein expression in SKBR3 cells was significantly higher (p<0.0001) than that of HER2-negative cells, with 100% analytical specificity and sensitivity. Following FISH, 100% of the cells were de-stained and presented sharp HER2/CEP17 foci, with 96% of the SKBR3 cells and only 4% of the Hs 578T cells displaying HER2 amplification. Additionally, in a small cohort of metastatic BC patients’, 100% of the identified CTCs are retained and evaluable from IF to FISH. Conclusions. An assay integrating HER2 identification by IF and FISH to characterize CTCs in metastatic BC patients was successfully developed. The assay enables the identification of both HER2 protein and gene copy information from each target cell with minimal cell loss, with the potential for minimally invasive patient monitoring during treatment and better classification of patients who may qualify and benefit from HER2-targeted therapies. An added value of the assay is the practicality of utilizing preserved blood samples, allowing streamline batch shipping of clinical samples." | gooosed | |
18/3/2024 15:36 | Of course there is a placing Rua shot to 50p placing 11pAll pharmas are placing These idiots at agl leave it until price is way down to place | beatme1 | |
18/3/2024 15:35 | From whom did you hear this Toasty? Reliable enough for you to take out a short from current price to 12p? | bagpuss67 | |
18/3/2024 13:47 | Yeah from what I heard 12p, unconfirmed reports Do your own research | havinthelasttoast | |
18/3/2024 08:20 | Placing on the way ? | havinthelasttoast | |
17/3/2024 19:30 | Apparently it's a her not him or maybe its was him that's turned into herWill let you pick the bones out of that | rb1947 | |
17/3/2024 17:04 | If they sacked him...this gives me confidence that the company knows what they're doing. | htrocka2 | |
15/3/2024 21:47 | Bermudashorts Probably not can you advise what revenues have been generated purely through cassette sales? | bones699 | |
15/3/2024 20:23 | bones - do you think Angle are giving away the cassettes used in these trials for free? | bermudashorts | |
15/3/2024 19:52 | Yup a few trials but as yet no sales made! | bones699 | |
15/3/2024 10:48 | radders/Mr K Another one to add to the list is the prostate cancer trial being run by Barts Cancer Institute. The study is using Parsortix to investigate the value of CTCs in predicting treatment failure in patients undergoing a radical prostatectomy. So trying to predict which patients are likely to have recurrence of their cancer who presumably can be flagged for closer monitoring and possibly any suitable adjuvant therapy. | bermudashorts | |
15/3/2024 09:19 | Bones699, think about your husband and children. They deserve more. You need to do better. It's over. Find another job and move on with your lives. | atmysignal | |
15/3/2024 09:16 | Osc - any potential market moving news relating to income etc have to be notified. | boris cobaka | |
15/3/2024 08:23 | Is anyone aware of this trial..... Study of Blood Markers of Tumor Dissemination in Patients With Versus Without Intestinal Polyps ? Mr K. | mrkeysersoze | |
14/3/2024 23:15 | You won't miss market expectations because you dont have any! | bones699 | |
14/3/2024 18:47 | What is giving me encouragement is that we haven't had a repeat of last Jan's "we are going to miss market expectations" So, to me anyway, it looks like Berenberg etc are reasonably happy with the revenue growth predictions that are out there. | outsizeclothes.com | |
14/3/2024 18:25 | Another day in the land of ah@t when nothing ever happens! More chance seeing a unicorn walking down Croydon highstreet than this bag of sh@t with its dodgey CEO signing any commercial deals.. Just an absolute f@@king basket case can't believe I bought on here over ten years ago and my average share price is 40p! | bones699 | |
14/3/2024 15:04 | AGL have updated their events calendar, including the AACR. | radderssandy | |
14/3/2024 14:55 | Another NEW role:-CLINICAL LAB DIRECTOR:CLD with specialist knowledge in cancer biology and genetics to lead the clinical laboratory team, manage interactions with our growing customer base, and oversee the running and expansion of our clinical laboratory.?-At ANGLE, we foster a dynamic, entrepreneurial approach to translating leading edge translational research into clinical diagnostics. We promote a culture of collaboration and shared excellence while encouraging an open and honest exchange of ideas. We are always in search of potential employees who share our vision and want to make a difference today. In your submission, please describe your background and what you can bring to our team along with attaching your resume.?-Principal Accountabilities: Lead an expanding clinical team by overseeing the running of the clinical lab.? Ensure compliance with all regulatory and quality management requirements.? Manage customer interactions in a professional manner.? Run multiple client projects simultaneously and be accountable for planning activities and follow-up meetings.? Generate accurate data reports with high quality results for clients in a timely manner.? Work closely with the Heads of R&D, Manufacturing and Regulatory to ensure seamless transfer and validation of new assays into the clinical laboratory to add to the service portfolio. This will involve detailed project management and working in multidisciplinary teams to deliver projects on time and within budget.? Contribute to company strategy and execution, ensuring strong representation of the clinical laboratory and excellent inter-departmental communications and interactions. Essential responsibilities as a member of the Senior Management Team (SMT).-https://angle | 5oletrader | |
14/3/2024 09:14 | 'Don't be daft, Bones can’t read 🤣' He must be able to read because he knows how to write lies. These caught everyone by surprise.... | htrocka2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions